# Expanded Access to Telisotuzumab Adizutecan

> **NCT05982873** · — · AVAILABLE · sponsor: **AbbVie**

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Telisotuzumab Adizutecan

## Key facts

- **NCT ID:** NCT05982873
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982873, "Expanded Access to Telisotuzumab Adizutecan". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT05982873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*